Peptides News and Research

RSS

Ajinomoto AminoScience introduces new resource for peptides

Ajinomoto AminoScience, LLC announced today the launch of AjiPhase™, an evolution of liquid phase peptide synthesis containing the benefits of solid and liquid phase methodologies. This new service is designed as an innovative tool that will enable pharmaceutical companies to expand their development pipeline and provide a uniform production process through the entire development lifecycle.

21 Apr 2010

Researchers identify potential drug target for treatment of Alzheimer's disease

Researchers at the University of Illinois have identified a potential drug target for the treatment of Alzheimer's disease: a receptor that is embedded in the membrane of neurons and other cells.

21 Apr 2010

ForteBio introduces new Octet QK(e) instrumentation system

ForteBio®, Inc., a leading supplier of label-free technology that accelerates the development of biotherapeutic and pharmaceutical products, today announced the launch of its new Octet QK(e) instrumentation system. The new system, the next generation of the company's initial eight-channel Octet QK instrument, provides significantly increased sensitivity, enabling analysis of small proteins and peptides. Additionally, the Octet QK(e) system enables biosensors to be re-racked, for increased workflow flexibility and cost savings.

20 Apr 2010

Certain genetic mutations lead to Type 1 diabetes: The Scripps Research Institute

Scientists from The Scripps Research Institute have provided an answer to the 40-year-old mystery of how certain genetic mutations lead to Type 1 diabetes. This new molecular understanding could lead to novel therapies for Type 1 diabetes and other autoimmune diseases.

20 Apr 2010

RegeneRx Biopharmaceuticals proposes common stock public offering

RegeneRx Biopharmaceuticals, Inc., a biopharmaceutical company focused on the development of a novel therapeutic peptide, Thymosin beta 4, for tissue and organ protection, repair and regeneration in cardiovascular diseases, central nervous system injuries, ophthalmic indications and dermal wounds, announced today that it intends to offer units consisting of shares of its common stock and warrants to purchase shares of its common stock in a public offering.

17 Apr 2010

New nanotechnology biomedical therapy for joint injuries

Dr. Nirav A. Shah, MD, an orthopaedic sports medicine surgeon affiliated with Palos Community Hospital is the first to design a new nanotechnology biomedical therapy that promotes the growth of new, stronger cartilage to aid in the treatment of joint injuries.

16 Apr 2010

Novel drug helps discover mechanisms underlying female sexual arousal

By using a novel prototype drug, researchers have discovered more about the mechanisms underlying female sexual arousal. These findings are published today in the British Journal of Pharmacology.

15 Apr 2010

UCCS, Texas A&M Health Science Center announce collaboration in bioenergetics, immunology and cell life

The University of Colorado at Colorado Springs will work collaboratively with the Texas A&M Health Science Center in the areas of bioenergetics, immunology and cell life, according to a memorandum of understanding between the two schools announced Monday, April 10.

12 Apr 2010

Tβ4 therapy for ocular disorders closer to reality

RegeneRx Biopharmaceuticals, Inc. announced today that Tβ4, a synthetic version of a naturally occurring peptide that is the basis for the company's product candidates, will be the subject of three poster presentations at the annual meeting of the Association for Research in Vision and Ophthalmology (ARVO) to be held in Fort Lauderdale, Florida from May 2-6, 2010.

9 Apr 2010

Researchers show iRGD peptide increases treatment efficacy against cancer

Researchers have shown that a peptide (a chain of amino acids) called iRGD helps co-administered drugs penetrate deeply into tumor tissue. The peptide has been shown to substantially increase treatment efficacy against human breast, prostate and pancreatic cancers in mice, achieving the same therapeutic effect as a normal dose with one-third as much of the drug.

9 Apr 2010

Nanotechnology-based vaccine cures mice with type 1 diabetes

Using a sophisticated nanotechnology-based "vaccine," researchers were able to successfully cure mice with type 1 diabetes and slow the onset of the disease in mice at risk for the disease. The study, co-funded by the Juvenile Diabetes Research Foundation, provides new and important insights into understanding how to stop the immune attack that causes type 1 diabetes, and could even have implications for other autoimmune diseases.

9 Apr 2010

Sanofi-Aventis acquires exclusive global rights to CureDM's Pancreate

CureDM, LLC announced today that an agreement has been signed with Sanofi-Aventis for the exclusive worldwide license of Pancreate™, a novel islet neogenesis agent for the treatment of type 1 and type 2 diabetes. CureDM is a privately held biopharmaceutical company whose scientists discovered Pancreate™, a first-in-class human peptide therapeutic. Several key Composition of Matter and Use patents have been issued to CureDM for this potentially transforming treatment approach for diabetes.

9 Apr 2010

Reliable immune monitoring tool for assessment of cancer vaccine-induced CD4+ T-cell response

A team of tumor immunologists in France and Switzerland has established an improved, reliable immune monitoring tool that allows for more accurate measurement of the number, subtype, and activity of cancer antigen-specific CD4+ T cells in cancer patients treated with therapeutic cancer vaccines. The new technology may significantly aid tumor immunologists around the world who are working to improve the effectiveness of this emerging and highly promising class of immune system-based cancer therapies.

8 Apr 2010

Role of beta defensins in development of chronic inflammatory response in the brain

Researchers at the Case Western Reserve University School of Dental Medicine and School of Medicine will look for evidence within the brain for human beta defensin peptide function-proteins important to the peripheral body's natural defense system against infection from the outside environment.

8 Apr 2010

Cephalon acquires biotechnology company, Ception Therapeutics

Cephalon, Inc. announced today that it has completed its previously announced acquisition of biotechnology company Ception Therapeutics, Inc. and that Ception is now a wholly-owned subsidiary of Cephalon.

6 Apr 2010

New report questions the kinetics of T cell receptors

T cell receptors are among the most important molecules in the immune system because of their role in recognizing the antigens that signal such threats as viruses and cancer. The receptors must also distinguish these threats from the body's own cells to avoid triggering an unwanted immune system response.

5 Apr 2010

Some therapies being investigated for Alzheimer's disease may cause cell death: UCSD

Some current therapies being investigated for Alzheimer's disease may cause further neural degeneration and cell death, according to a breakthrough discovery by UC San Diego researchers. By combining three dimensional computer simulations with high resolution atomic force microscopy membrane protein and cell imaging, electrical recording and various cellular assays, UCSD nano-biophysicist Ratnesh Lal and his colleagues investigated the structure and function of truncated peptides, known as nonamyloidgenic peptides, formed by some Alzheimer's drug candidates.

5 Apr 2010

Cancer research at Georgia Tech: Report

Cancer treatment typically involves surgery, radiation therapy, chemotherapy, hormone therapy or biological therapy. An oncologist may use one therapy or a combination of methods, depending on the type and location of the cancer, whether the disease has spread, the patient's age and general health, and other factors.

3 Apr 2010

Study could aid in developing new, effective treatments for prostate cancer

Van Andel Research Institute (VARI) scientists have determined how two proteins required for the initiation and development of prostate cancer interact at the molecular level, which could lead to improved treatments for the disease.

3 Apr 2010